联系客服QQ:86259698

600479 沪市 千金药业


首页 公告 千金药业:千金药业2025年一季度主要经营数据公告

千金药业:千金药业2025年一季度主要经营数据公告

公告日期:2025-04-29


  证券代码:600479      证券简称:千金药业        公告编号:2025-029
            株洲千金药业股份有限公司

          2025 年一季度主要经营数据公告

  本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。

  根据《上市公司行业信息披露指引第六号——医药制造》及《关于做好主板上市公司 2025 年第一季度报告披露工作的重要提醒》的要求,公司现将 2025 年第一季度主要经营数据披露如下:

  一、报告期内公司主营业务分行业经营情况

                                      单位:元 币种:人民币

                                                营业  营业

                                                收入  成本  毛利率
 分行业    营业收入        营业成本    毛利  比上  比上  比上年
                                        率(%) 年同  年同  同期增
                                                期增  期增  减(%)
                                              减(%) 减(%)

 药品生                                                            减少

  产    530,222,497.67  175,258,545.39  66.95  7.21  11.75  1.34 个
                                                                  百分点

 中药材                                                            减少

 及饮片    15,719,733.38    14,157,680.18  9.94  -24.25 -19.24 5.59 个
 生产                                                            百分点

 药品批                                                            减少

 发零售  407,124,751.10  342,963,381.16  15.76  -6.54  -5.37 1.04 个
                                                                  百分点

                                                                  减少

 其他    75,476,534.33    32,278,561.77  57.23  42.83  60.17  4.63 个
                                                                  百分点

 合并抵  -44,661,595.61  -43,802,770.91

  销


                                                                  增加

 合计    983,881,920.87  520,855,397.59  47.06  -0.46  -3.78 1.83 个
                                                                  百分点

  二、报告期内公司主营业务分产品经营情况

                                    单位:元 币种:人民币

                                              营业收  营业成  毛利率
分产                                  毛利  入比上  本比上  比上年
 品      营业收入        营业成本    率(%) 年同期  年同期  同期增
                                              增减    增减  减(%)
                                              (%)  (%)

中药                                                              减少

生产  245,847,372.63    87,285,713.79  64.50  5.09    10.67  1.79 个
                                                                  百分点

西药                                                              减少

生产  284,375,125.04    87,972,831.60  69.06  9.11    12.85  1.02 个
                                                                  百分点

中药

材及    15,719,733.38    14,157,680.18    9.94  -24.25  -19.24  减少

饮片                                                              5.59 个
生产                                                              百分点

药品                                                              减少

批发  407,124,751.10  342,963,381.16  15.76  -6.54  -5.37  1.04 个
零售                                                              百分点

                                                                  减少

娱乐    15,122,758.46    5,997,950.27    60.34  51.20  54.25  0.78 个
                                                                  百分点

卫生                                                              减少

用品    57,847,657.44    24,466,903.22  57.70  41.76  61.69  5.21 个
                                                                  百分点

                                                                  减少

其他    2,506,118.43    1,813,708.28    27.63  23.16  60.22  16.74
                                                                  个百分
                                                                  点

合并  -44,661,595.61  -43,802,770.91
抵消

                                                                  增加

合计  983,881,920.87  520,855,397.59  47.06  -0.46  -3.78  1.83 个
                                                                  百分点

  三、报告期内公司主营业务分地区经营情况

                                      单位:元 币种:人民币

    地区      2025 年 1-3 月累计主营业务收入  营业收入比上年同期增减
                                                      (%)

    华东              144,279,134.63                  23.63

    华南              63,611,604.84                    -8.31

    华北              45,913,742.85                    13.96

    华中              552,693,152.15                  -8.33

    东北              23,072,793.31                    11.05

    西南              109,129,117.47                  17.71

    西北              45,182,375.63                    -1.03

    合计              983,881,920.87                  -0.46

说明:

  报告期内,娱乐板块营业收入较上年同期增长 51.20%,营业成本较上年同期增长 54.25%,主要是由于春节档电影放映业务有所回暖所致;

  卫生用品板块收入较上年同期增长 41.76%,营业成本较上年同期增长 61.69%。主要是由于当前环境下,医护级卫生巾更能满足女性对健康和安全的需求,促使销售实现增长,同时公司加大促销及推广引流的力度,收入增长的同时成本也有所增长所致。

  上述的主要经营数据信息来源于公司报告期内财务数据,且未经审计,敬请广大投资者审慎使用,注意风险。

  特此公告。

                                  株洲千金药业股份有限公司
                                          董事会

                                      2025 年 4 月 29 日